TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05416307: Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Sponsor: Electra Therapeutics Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 156 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,118,808

Rescue Site Savings

+$2,065,704

Unlock Full NCT05416307 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05416307 Rescue Dossier →